The Vioxx® legacy: Enduring lessons from the not so distant past

Cardiology Journal

Volumn 21, Issue 2, 2014, Pages 203-205

  McIntyre, William F ^a,b   Evans, Gerald ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; IBUPROFEN; NAPROXEN; PRUCALOPRIDE; ROFECOXIB; CYCLOOXYGENASE 2 INHIBITOR; LACTONE; SULFONE;

CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; NOTE; OSTEOARTHRITIS; THROMBOCYTE FUNCTION; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DRUG APPROVAL; DRUG RECALL; HISTORY; PATIENT SAFETY; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DRUG APPROVAL; HISTORY, 21ST CENTURY; HUMANS; LACTONES; PATIENT SAFETY; RISK ASSESSMENT; SAFETY-BASED DRUG WITHDRAWALS; SULFONES;

EID: 84898630594     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.2014.0029     Document Type: Note

References (10)

1. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med, 2000; 343: 1520-1528.
2. Curfman GD, Morrissev S, Drazem JM. Expression of concern: Bombardier et al. "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis". N Engl J Med, 2000; 343: 1520-1528. N Engl J Med, 2005; 353: 2813-2814.
3. Bresalier RS, Sandler RS, Quan H et al. CV events associated with rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N Engl J Med, 2005; 352: 1092-1102.
4. Merck, "News Release: Merck Announces Voluntary Withdrawal of Vioxx®", September 30, 2004, http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf.
5. Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ, 2002; 167: 1131-1137.
6. Prakash S, Valentine V. Timeline: The Rise and Fall of Vioxx. November 10, 2007, http://www.npr.org/templates/story/story.php?storyId=5470430.
7. Wilson D. Merck to Pay $950 Million Over Vioxx. New York Times. November 22, 2011, http://www.nytimes.com/2011/11/23/ business/merck-agrees-to-pay-950-million-in-vioxx-case.html.
8. Zwillich T. How Vioxx is changing US drug regulation. Lancet, 2005; 366: 1763-1764.
9. Langlitz N. Pharmacovigilance and post-black market surveillance. Soc Stud Sci, 2009; 39: 395-420.
10. Armstrong PW. Balancing the cyclooxygenase portfolio. CMAJ, 2006; 174: 1581-1582.